User:Amanda1515/sandbox

Background: Michael Yu was born in February, 1964. He earned his doctorate degree in Molecular Genetics from the Chinese Academy of Sciences (Shanghai, China) and completed his post-doctoral training at the University of California San Francisco (UCSF, USA) where he worked for two years thereafter. Dr. Michael Yu is a distinguished expert under China’s “Thousand Talents Program”. What is more, Michael Yu is the inventor of the world’s first oncolytic virus product, Oncorine (an oncology product) and China’s first novel antibody product, Conbercept (a drug for ocular diseases and oncology), which has made him the only Chinese scientist who has invented and successfully developed two ‘Class I’ drugs in China. Dr. Yu was a co-founder, President and CEO of Chengdu Kanghong Biotech since its inception in 2006 until 2011. Dr. Yu was Vice President of Research and Development at Applied Genetics (NASDAQ: AGTC) and Calyton (USA). The latter was acquired by Cell Genesys (NASDAQ: CEGE) in 2001 where he worked for three years following the acquisition. Founder, CEO and President of Innovent Biologics (2011-Present) Dr. Yu founded Innovent Biologics in August 2011. Innovent aims to produce quality complex biopharmaceutical products that will be affordable to people in China and around the world. With its focus on innovation and global cGMP standards, Innovent stands out among China’s biopharmaceutical industry and has attracted investments from world-class financial firms such as Fidelity, Lilly Asia Ventures, Legend Capital, SDIC Fund Management, China Life, Temasek, Hillhouse, Ping An, Taikang Insurance Group, and others. In 2015, Innovent entered a strategic alliance with Eli Lilly & Company to co-develop and co-commercialize multiple innovative biologics in China, while Lilly develops and commercializes multiple immuno-oncology biologics outside China. The transaction not only brought the largest upfront payment from a global company to a Chinese company, but also was the first time a biologic was out-licensed to a global company for global development. Scientific Roles and Responsibilities Dr. Yu acts as deputy director of National Standardization Committee for Biochemistry Products and Testing Technology, professor at Sichuan University, the visiting professor of Zhejiang University, the deputy director of Shanghai Engineering Research Center for cell therapy, the executive director of China Pharmaceutical Biotechnology Association, the member of China Anticancer Association Cancer Biotherapy Specialized Committee, the Standing Committee member of China Association of Biotechnology and Gene Therapy, the Standing Committee member of China Medical Biotechnology Association Precision Medical Specialized Committee. Awards and international recognition Dr. Yu is one of the key founders of Oncolytic Virotherapy, he is the inventor and owner of 61 patents(including 36 United States patents). As the only Chinese scientist who has invented and successfully developed two ‘Class I’ drugs in China, Dr. Yu is one of the few domestic scientists who have a strong ability to innovate and develop drugs that will be beneficial to the majority of patients. At the same time, Dr Yu has published more than 60 scientific articles, papers and monographs. 	National “Person of the Year in Innovation for Science and Technology in 2016” In January 2017 	“Most Influential Overseas Returnee in Life Sciences” in 2013. 	“Top Ten Figure of Innovation in China” in 2014. 	“E&Y Entrepreneur of the Year 2015” awards in China in 2015 	“Mayor Award on Scientific and Technological Innovation and Entrepreneurship of Suzhou” in 2015. 	“Distinguished Entrepreneur of Jiangsu Province”in 2016 	“Top Ten Outstanding Science and Technology Innovation Entrepreneurs of Jiangsu Province”in 2016. 	“Top Ten Scientific and Technological Entrepreneurs of Suzhou city”in 2016. References 1. "千人计划"入选者俞德超：打开一个光明新“视”界 ．新华网[引用日期2014-05-22] 2. 赵忠贤等获选2016年度科技创新人物 ．人民网[引用日期2017-01-24] 3. 基因工程腺病毒及其用途 ．SOOPAT．1998-7-15[引用日期2013-12-26] 4. VEGF受体融合蛋白在治疗眼睛疾病中的应用 ．SOOPAT．2006-3-31[引用日期2013-12-26] 5. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains ．worldwide.espacenet.com[引用日期2013-12-26] 6. 国家食品药品监督管理总局批准康柏西普眼用注射液．国家食品药品监督管理总局[引用日期 2013-12-04] 7. 眼用注射液上市 “一滴水”让盲人重见光明 ．搜狐．2013-12-05[引用日期2013-12-26]

Michael Yu
Background: Michael Yu was born in February, 1964. He earned his doctorate degree in Molecular Genetics from the Chinese Academy of Sciences (Shanghai, China) and completed his post-doctoral training at the University of California San Francisco (UCSF, USA) where he worked for two years thereafter. Dr. Michael Yu is a distinguished expert under China’s “Thousand Talents Program”. What is more, Michael Yu is the inventor of the world’s first oncolytic virus product, Oncorine (an oncology product) and China’s first novel antibody product, Conbercept (a drug for ocular diseases and oncology), which has made him the only Chinese scientist who has invented and successfully developed two ‘Class I’ drugs in China. Dr. Yu was a co-founder, President and CEO of Chengdu Kanghong Biotech since its inception in 2006 until 2011. Dr. Yu was Vice President of Research and Development at Applied Genetics (NASDAQ: AGTC) and Calyton (USA). The latter was acquired by Cell Genesys (NASDAQ: CEGE) in 2001 where he worked for three years following the acquisition. Founder, CEO and President of Innovent Biologics (2011-Present) Dr. Yu founded Innovent Biologics in August 2011. Innovent aims to produce quality complex biopharmaceutical products that will be affordable to people in China and around the world. Scientific Roles and Responsibilities Dr. Yu acts as deputy director of National Standardization Committee for Biochemistry Products and Testing Technology, professor at Sichuan University, the visiting professor of Zhejiang University, the deputy director of Shanghai Engineering Research Center for cell therapy, the executive director of China Pharmaceutical Biotechnology Association, the member of China Anticancer Association Cancer Biotherapy Specialized Committee, the Standing Committee member of China Association of Biotechnology and Gene Therapy, the Standing Committee member of China Medical Biotechnology Association Precision Medical Specialized Committee. Awards and international recognition Dr. Yu is one of the key founders of Oncolytic Virotherapy, he is the inventor and owner of 61 patents(including 36 United States patents). As the only Chinese scientist who has invented and successfully developed two ‘Class I’ drugs in China, Dr. Yu is one of the few domestic scientists who have a strong ability to innovate and develop drugs that will be beneficial to the majority of patients. At the same time, Dr Yu has published more than 60 scientific articles, papers and monographs. 	National “Person of the Year in Innovation for Science and Technology in 2016” In January 2017 	“Most Influential Overseas Returnee in Life Sciences” in 2013. 	“Top Ten Figure of Innovation in China” in 2014. 	“E&Y Entrepreneur of the Year 2015” awards in China in 2015 	“Mayor Award on Scientific and Technological Innovation and Entrepreneurship of Suzhou” in 2015. 	“Distinguished Entrepreneur of Jiangsu Province”in 2016 	“Top Ten Outstanding Science and Technology Innovation Entrepreneurs of Jiangsu Province”in 2016. 	“Top Ten Scientific and Technological Entrepreneurs of Suzhou city”in 2016. References 1. "千人计划"入选者俞德超：打开一个光明新“视”界 ．新华网[引用日期2014-05-22] 2. 赵忠贤等获选2016年度科技创新人物 ．人民网[引用日期2017-01-24] 3. 基因工程腺病毒及其用途 ．SOOPAT．1998-7-15[引用日期2013-12-26] 4. VEGF受体融合蛋白在治疗眼睛疾病中的应用 ．SOOPAT．2006-3-31[引用日期2013-12-26] 5. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains ．worldwide.espacenet.com[引用日期2013-12-26] 6. 国家食品药品监督管理总局批准康柏西普眼用注射液．国家食品药品监督管理总局[引用日期 2013-12-04] 7. 眼用注射液上市 “一滴水”让盲人重见光明 ．搜狐．2013-12-05[引用日期2013-12-26]